Drug Type Small molecule drug |
Synonyms ABDNAZ, 1-溴乙酰基-3,3-二硝基氮杂环丁烷, RRX 001 + [2] |
Target |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), MYC inhibitors(Myc proto-oncogene protein inhibitors), NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC5H6BrN3O5 |
InChIKeyJODKFOVZURLVTG-UHFFFAOYSA-N |
CAS Registry925206-65-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 3 | US | 24 Dec 2018 | |
Squamous cell carcinoma of the oral cavity | Phase 2 | US | 12 Jul 2018 | |
Squamous Cell Carcinoma of the Oropharynx | Phase 2 | US | 12 Jul 2018 | |
Stomatitis | Phase 2 | US | 12 Jul 2018 | |
Advanced Cholangiocarcinoma | Phase 2 | US | 16 Jul 2015 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 2 | US | 01 Jun 2015 | |
Neuroendocrine Tumors | Phase 2 | US | 01 Jun 2015 | |
Refractory Ovarian Carcinoma | Phase 2 | US | 01 Jun 2015 | |
Small Cell Carcinoma | Phase 2 | US | 01 Jun 2015 | |
Metastatic Colorectal Carcinoma | Phase 2 | US | 01 May 2014 |
Phase 2 | 4 | iqnqvqfgxh(mjlxlheqhr) = dnkdlampmk zneddttamo (sgcteetzrq, hlyftgswcf - vhagbppdna) View more | - | 24 Apr 2024 | |||
Phase 2 | Solid tumor Third line | 40 | npsobmrcxl(nbiitytcwh) = ytainvjwmi cuntmbofqo (lhrjvxhshd ) View more | Positive | 21 Feb 2023 | ||
Phase 2 | Colorectal Cancer Third line | 34 | wonrjjtgxu(lpxysygjxk) = zuyzxcauew izxcicksik (huenywzjye ) View more | Positive | 24 Jan 2023 | ||
wonrjjtgxu(lpxysygjxk) = jgwkwhuzks izxcicksik (huenywzjye ) View more | |||||||
Phase 2 | 53 | cyqfittifu(sgaahomdey) = RRx-001 were well tolerated with no associated serious adverse events zhfsllmhbi (ggytywdqrz ) View more | Positive | 02 Jun 2022 | |||
Standard-of-care | |||||||
Phase 1/2 | 31 | Radiation Therapy+RRx-001 | udfkttdext(qizplpiyzu) = cqdlwrevry uzpvtozobw (ffyrccpizp ) View more | Positive | 01 Jul 2020 | ||
NCT02518958 (ASCO2020) Manual | Phase 1 | 12 | vdoxdigdvc(ubkuxwgomc) = pain on infusion (33.3%) vyfeetmfal (agcbpcapwq ) View more | Positive | 29 May 2020 | ||
Phase 1 | 12 | oqxhprrfjm(xiprnyouvn) = 2 events (leukopenia and anemia only related to irinotecan) mhwnhlhbsn (mrwvhyrdhx ) View more | Positive | 29 May 2020 | |||
Phase 2 | 53 | tlufehzgfd(thciokbxzn) = rdjyenhrhp toevtstuqm (zpemobfvlz ) | Positive | 25 May 2020 | |||
(Standard of care) | tlufehzgfd(thciokbxzn) = ocvgghhvap toevtstuqm (zpemobfvlz ) | ||||||
Phase 2 | 18 | dmdumxcpiw(dmtxsftlyf) = The main adverse event attributed to RRx-001 treatment, which involved once weekly peripheral or central infusion, was a painful infusion-related superficial phlebitis in 80% of patients. oskpyoiuqb (qcsbpjhfro ) View more | Positive | 25 May 2020 | |||
Phase 2 | 139 | kqvoriusbo(gefnyldtzi) = unsjkvhaqe zjafytmkmt (vbdbxawqcg ) View more | - | 01 Jul 2019 |